Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.

"the data have been submitted to sequence readarchive (sra) database with prjna number prjna781787 and prjna782086.; the data have been submitted to ncbi pride database with pxd number pxd029867.; the data have been submitted to ncbi pride database with pxd number pxd029975."

"CONFLICT OF INTEREST Nothing to report."

"This work was supported by grants from the National Key R&D Plan of China “Research on Modernization of Traditional Chinese Medicine” program (2018YFC1704200), the National Natural Science Foundation of China (81830113, 81870420, and 82070590), the Major Basic and Applied Basic Research Projects in Guangdong Province of China (2019B030302005), and the Special Topics of General Projects of Guangzhou Science and Technology Plan of China (201904010075). Conceptualization: Jiao Guo; Project administration: Jiao Guo; Funding acquisition: Jiao Guo, Tian Lan; Visualization: Tian Lan, Shuo Jiang, Jing Zhang, Qiqing Weng, Yang Yu, and Haonan Li; Writing – original draft: Tian Lan, Shuo Jiang, Jing Zhang, and Qiqing Weng; Writing – review & editing: Tian Lan, Shuo Jiang, Jing Zhang, Qiqing Weng, and Sha Hu; Investigation: Shuo Jiang, Jing Zhang, Qiqing Weng, Yang Yu, Haonan Li, and Song Tian; Data curation: Shuo Jiang, Jing Zhang, Qiqing Weng, Xin Ding, Yiqi Yang, Weixuan Wang, Lexun Wang, Duosheng Luo, Xue Xiao, Shenghua Piao, Qing Zhu, and Xianglu Rong; Supervision: Jiao Guo"